Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Update

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) was the recipient of a significant decrease in short interest in January. As of January 30th, there was short interest totaling 13,496 shares, a decrease of 47.6% from the January 15th total of 25,740 shares. Approximately 0.4% of the company’s stock are sold short. Based on an average daily trading volume, of 103,809 shares, the short-interest ratio is currently 0.1 days. Based on an average daily trading volume, of 103,809 shares, the short-interest ratio is currently 0.1 days. Approximately 0.4% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a research report on Wednesday, January 28th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Kiora Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Kiora Pharmaceuticals Price Performance

KPRX remained flat at $2.08 during midday trading on Friday. 8,280 shares of the company’s stock traded hands, compared to its average volume of 83,247. The firm has a 50 day moving average of $2.13 and a 200-day moving average of $2.37. The firm has a market cap of $7.65 million, a price-to-earnings ratio of -1.00 and a beta of -0.82. Kiora Pharmaceuticals has a 1-year low of $1.76 and a 1-year high of $4.18.

Institutional Investors Weigh In On Kiora Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in KPRX. DRW Securities LLC raised its stake in Kiora Pharmaceuticals by 199.2% during the 4th quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock valued at $217,000 after buying an additional 73,417 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in shares of Kiora Pharmaceuticals in the 4th quarter worth $152,000. Citadel Advisors LLC bought a new stake in shares of Kiora Pharmaceuticals in the third quarter worth $125,000. Renaissance Technologies LLC increased its position in Kiora Pharmaceuticals by 71.0% during the fourth quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock valued at $42,000 after acquiring an additional 8,800 shares during the last quarter. Finally, Two Sigma Investments LP bought a new position in Kiora Pharmaceuticals in the third quarter valued at about $33,000. Hedge funds and other institutional investors own 76.97% of the company’s stock.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.